A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
Active, not recruitingCTIS2022-501342-29-00
Merck Sharp & Dohme LLCEsophageal Carcinoma
Start: 2021-07-21Target: 171Updated: 2025-10-09